Cryoport, Inc. (CYRX) is a Healthcare stock trading at $17.11 (as of 2026-08-21), with a market capitalization of $866.86M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Cryoport provides temperature-controlled logistics for life sciences shipments, and it makes money by managing biologic supply chain execution (through Cryoportal, a cloud logistics platform, and CryoPort Express Shippers) including shipment order entry, documentation, customs support, courier coordination, real-time tracking, issue resolution, and regulatory compliance.
Cryoport's profit engine is the recurring, shipment-by-shipment execution required to keep biologics stable and compliant, so results depend on how many clinical trials and commercial cell and gene therapy programs it supports, and how consistently it converts that demand into logistics and related platform service revenue.
Business quality (Weak): Good disclosure of operating trial-support counts and revenue category labels, but the data provided here does not clearly map to official, mutually exclusive reportable segments.
Valuation: At 10× earnings, CYRX trades 39% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $17.11 |
| Market Cap | $866.86M |
| Price / Book | 1.77 |
| Price / Sales | 4.65 |
| FCF Yield | -2.3% |
| Revenue (TTM) | $176.18M |
| Net Margin | 44.4% |
| Revenue Growth (YoY) | 7.7% |
| EPS Growth (YoY) | -109.8% |
| FCF Growth (YoY) | -31.8% |
| Altman Z-Score | 1.17 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | CADIAN CAPITAL MANAGEMENT, LP ($39.55M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 6 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Jerrell W. Shelton |
| Employees | 1,090 |
| Country | US |
| IPO Date | 2005-08-22 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.